Sphera Funds Management’s Summit Therapeutics SMMT Stock Holding History

Sphera Funds Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-212,018	Closed	-$2.35M	–	139
2017 Q4	$2.35M	Hold	212,018	–	–	0.28%	82
2017 Q3	$2.65M	Buy	212,018 +70,000	+49%	+$907K	0.38%	70
2017 Q2	$1.56M	Sell	142,018 -5,432	-4%	-$61.2K	0.27%	93
2017 Q1	$1.97M	Hold	147,450	–	–	0.38%	71
2016 Q4	$1.26M	Sell	147,450 -50,000	-25%	-$534K	0.32%	77
2016 Q3	$1.81M	Hold	197,450	–	–	0.3%	77
2016 Q2	$1.56M	Sell	197,450 -1,413	-0.7%	-$11.5K	0.41%	65
2016 Q1	$1.39M	Sell	198,863 -3,357	-2%	-$27.2K	0.3%	71
2015 Q4	$2.32M	Sell	202,220 -2,980	-1%	-$31K	0.34%	74
2015 Q3	$2.14M	Hold	205,200	–	–	0.27%	88
2015 Q2	$2.28M	Buy	205,200 +30,200	+17%	+$342K	0.22%	107
2015 Q1	$2.17M	Buy	+175,000	New	+$1.98M	0.23%	102

Other funds holding SMMT

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Sphera Funds Management's SMMT Position: Q1 2018 in Review

Sphera Funds Management sold out of Summit Therapeutics (SMMT) in Q1 2018, closing a stake of 212,018 shares — an estimated $2.35M sold.

Sphera Funds Management first reported a position in SMMT in Q1 2015 and held it in 12 quarters. The position peaked at $2.65M in Q3 2017. 20 funds tracked by Wall St. Rank hold SMMT as of Q1 2018.

Sphera Funds Management reported no remaining Summit Therapeutics position as of Q1 2018 after selling out during the quarter.
Sphera Funds Management sold 212,018 Summit Therapeutics shares in Q1 2018, an estimated $2.35M.
Sphera Funds Management first reported a position in Summit Therapeutics in Q1 2015 and held it in 12 quarters.
Sphera Funds Management's Summit Therapeutics position peaked at $2.65M in Q3 2017.
20 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.